Method of treating disorders using a pharmaceutical composition of oligopeptides

Patent metadata

Field	Value
Publication number	US-10478501-B2
Application number	US-201214122956-A
Country	US
Kind code	B2
Filing date	May 16, 2012
Priority date	Jun 9, 2011
Publication date	Nov 19, 2019
Grant date	Nov 19, 2019

Abstract

The present invention relates to a pharmaceutical composition of oligopeptides, preferably cyclic oligopeptides, said composition further comprising one or more lipophilic and/or amphiphilic compounds, in the presence or absence of water as the main ingredients, the use of the lipophilic and/or amphiphilic compounds for making pharmaceutical compositions of said oligopeptides, and methods of making said pharmaceutical composition.

First claim

The invention claimed is:

1. A method for the treatment of cancer wherein said cancer expresses αvβ3 and/or αvβ5 integrins, comprising a step of subcutaneously and/or intramuscularly administering to a patient who has been identified as having a cancer which expresses αvβ3 and/or αvβ5 integrins an effective amount of a composition which is a suspension comprising:
a) 12 to 90% of the oligopeptide cyclo-(Arg-Gly-Asp-DPhe-NMeVal) having a solubility in water at 20° C. between 3 mg/ml and 10 mg/ml,
b) 0.01 to 60% of one or more lipophilic and/or amphiphilic compounds having a molar weight in the range of 200 g/mol to 2000 g/mol, and optionally
c) 0 to 87.99% of water, with the proviso that the sum of a), b) and c) sums up to 80 or more percent of the total composition with the proviso that said suspension composition contains 100 mg/ml or more of said oligopeptide, and with the further proviso that said suspension composition comprises 40% or more of said oligopeptide as solid particles.

2. The method according to claim 1 , wherein said composition is a pharmaceutical composition.

3. The method according to claim 1 , wherein said patient is a human.

4. The method as claimed in claim 1 , wherein in said composition at least one of the one or more lipophilic and/or amphiphilic compounds according to b) comprises:
i) a glycerol moiety,
ii) one or more fatty acid moieties, and/or
iii) one or more fatty alcohol moieties.

5. The method as claimed in claim 1 , wherein in said composition at least one of the one or more amphiphilic compounds according to b) comprises a hydrophilic moiety.

6. The method according to claim 5 , wherein in said composition the hydrophilic moiety comprises an ethanolamine moiety, a choline moiety, a phosphatidyl moiety, a sulfatidyl moiety, and/or a salt thereof.

7. The method as claimed in claim 5 , wherein in said composition the hydrophilic moiety comprises an phosphoethanolamine moiety, a phosphatidylcholine moiety, a phosphatidylglycerol moiety, a sulfatidylglycerol moiety, and/or a salt thereof.

8. The method as claimed in claim 6 , wherein in said composition the hydrophilic moiety comprises an phosphoethanolamine moiety, a phosphatidylcholine moiety, a phosphatidylglycerol moiety, a sulfatidylglycerol moiety, and/or a salt thereof.

9. The method according to claim 1 , wherein in said composition the one or more lipophilic compounds according to b) comprise one or more compounds selected from natural oils and synthetic oils, and mixtures thereof, and/or wherein the one or more amphiphilic compounds according to b) comprise one or more compounds selected from amphiphilic lipids having phosphatidyl-polyol or sulfatidyl-polyol groups as the hydrophilic part, and derivatives, salts and/or alcoholates thereof.

10. The method according to claim 9 , wherein in said composition the phosphatidyl- or sulfatidyl-polyoles are selected from
a) polyphosphatidylglycerol, triphosphatidylglycerol, diphosphatidylglycerol, monophosphatidylglycerol, and/or
b) polysulfatidylglycerol, trisulfatidylglycerol, disulfatidylglycerol, and monosulfatidylglycerol.

11. The method according to claim 1 , wherein, in said composition the amphiphilic compounds are selected from the group consisting of dioleoylphosphatidylglycerol, dimyristoylphosphatidylglycerol, dimyristoylphosphatidylcholine, distearoylphosphatidylglycerol, dioleoylglycerophosphocholine, dipalmitoylglycerophosphoglycerol, distearoylglycerophosphoethanolamine, egg phosphatidylcholine, soy phosphatidylcholine, and pharmaceutically acceptable derivatives, salts and alcoholates thereof.

12. The method according to claim 1 , wherein, in said composition the amphiphilic compounds are selected from the group consisting of dioleoylphosphatidylglycerol, dimyristoylphosphatidylglycerol, and pharmaceutically acceptable derivatives, salts and alcoholates thereof.

13. The method according to claim 1 , wherein the oligopeptide in said composition comprises solid cyclo-(Arg-Gly-Asp-DPhe-NMeVal) in a polymorphic form having crystallographic unit cell with the lattice parameters: a=9.8±0.1 Å, b=19.5±0.5 Å, and c=15.4±0.1 Å.

14. The method as claimed in claim 1 , wherein, the ratio between the amphiphilic compounds and the oligopeptide is in the range between 0.01 and 0.5 or is in the range between 0.001 and 0.05.

15. The method according to claim 1 , wherein said cancer is metastatic.

16. The method according to claim 15 , wherein said metastases are selected from bone metastases, lung metastases, liver metastases and brain metastases.

17. The method according to claim 1 , wherein the cancer is selected from breast cancer, lung cancer, head and neck cancer, prostate cancer, brain cancer, colorectal cancer, liver cancer and malignant melanoma.

18. The method according to claim 17 , wherein, the lung cancer is selected from non-small cell carcinoma (NSCLC) and small cell carcinoma (SCLC), the head and neck cancer is squamous cell carcinoma of the head and neck (SCCHN), the liver cancer is hepatocellular carcinoma and/or the brain cancer is selected from astrocytoma, gliblastoma and glioblastoma multiforme.

19. The method according to claim 1 , wherein, said patient receives radiotherapy.

20. The method according to claim 1 , wherein, said method further comprises administering radiotherapy concurrently or consecutively to said patient.

21. The method according to claim 20 , wherein, the radiotherapy is selected from radioimmunotherapy and external beam radiation.

22. The method according to claim 16 , wherein, the treatment of the bone metastases comprises or induces:
a) reduced bone resorption,
b) new bone formation,
c) regulation or normalisation of the osteoclast activity,
d) resumption of bone formation and
e) regrowth of bone or partial re-growth of the bone,

in said subject.

23. The method according to claim 1 , wherein said suspension composition comprises 150 to 300 mg/ml of said oligopeptide.

24. The method according to claim 1 , wherein said suspension composition comprises 70% or more of said oligopeptide in the form of solid particles.

25. The method according to claim 1 , wherein said suspension composition comprises 150 to 300 mg/ml of said oligopeptide and wherein 70% or more of said oligopeptide is contained in the form of solid particles.

Assignees

• Goodman Simon
• Amendt Christiane
• Eber Marcus
• Merck Patent Gmbh

Inventors

• Goodman Simon
• Amendt Christiane
• Eber Marcus

Classifications

• A61K9/14

  Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)} · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K2039/54

  characterised by the route of administration · CPC title

• A61K39/39558

  against tumor tissues, cells, antigens · CPC title